AtriCure, Inc. $ATRC Holdings Lifted by Grandeur Peak Global Advisors LLC

Grandeur Peak Global Advisors LLC grew its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 53.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 587,399 shares of the medical device company’s stock after purchasing an additional 205,497 shares during the period. AtriCure accounts for about 4.0% of Grandeur Peak Global Advisors LLC’s investment portfolio, making the stock its 6th largest position. Grandeur Peak Global Advisors LLC owned about 1.15% of AtriCure worth $16,435,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ATRC. AQR Capital Management LLC lifted its stake in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after buying an additional 837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in AtriCure by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after acquiring an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the period. Jane Street Group LLC grew its stake in AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares during the period. Finally, Strs Ohio acquired a new position in AtriCure in the 1st quarter valued at $158,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insider Transactions at AtriCure

In other AtriCure news, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the sale, the director owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Vinayak Doraiswamy sold 6,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 53,616 shares of company stock valued at $2,149,994 in the last ninety days. Company insiders own 4.00% of the company’s stock.

AtriCure Stock Performance

NASDAQ:ATRC opened at $48.54 on Monday. The company has a market cap of $2.47 billion, a P/E ratio of 231.15 and a beta of 1.20. The firm’s 50 day moving average is $37.89 and its two-hundred day moving average is $32.22. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.98. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts expect that AtriCure, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ATRC shares. UBS Group reduced their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Canaccord Genuity Group raised their price target on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, BTIG Research lifted their price target on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.89.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.